Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results
July 30, 2020Second Quarter and First Half 2020
– Second Quarter Product Sales of $5.1 billion –
– First Half Product Sales of $10.5 billion –
– Second Quarter GAAP Loss of $(2.66) per share –
– Second Quarter Non-GAAP Diluted EPS of $1.11 per share –
Revised Full Year 2020 Guidance
– Product Sales of $23 billion to $25 billion –
– Non-GAAP Diluted EPS of $6.25 to $7.65 per share –
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020.
“Gilead’s first half performance demonstrates the strength and durability of our core HIV business, even as we navigated the expected impact of the COVID-19 pandemic. We are already starting to see early signs of recovery from this impact and we are fully confident in our long-term HIV leadership,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. (Read more…) “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”
Financial Results
- Total revenues for the second quarter and first half 2020 were $5.1 billion and $10.7 billion, respectively, compared to $5.7 billion and $11.0 billion, respectively, for the same periods in 2019.
- GAAP net loss and diluted loss per share for the second quarter 2020 were $(3.3) billion and $(2.66), respectively, compared to net income and diluted EPS of $1.9 billion and $1.47, respectively, for the same period in 2019.
- GAAP net loss for the second quarter 2020 included an acquired in-process research and development (“IPR&D”) charge of $4.5 billion related to Gilead’s acquisition of Forty Seven, Inc (“Forty Seven”).
- Non-GAAP net income and diluted EPS for the second quarter 2020 were $1.4 billion and $1.11, respectively, compared to $2.2 billion and $1.72, respectively, for the same period in 2019.
- Gilead’s core business delivered a solid performance, despite the global impacts of COVID-19.
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||||
|
(In millions, except per share amounts) |
|
2020 |
|
|
2019 |
|
2020 |
|
|
2019 |
|||||||||
|
Product sales |
|
$ |
5,067 |
|
|
|
$ |
5,607 |
|
|
$ |
10,534 |
|
|
|
$ |
10,807 |
|
|
|
Royalty, contract and other revenues |
|
76 |
|
|
|
78 |
|
|
157 |
|
|
|
159 |
|
|||||
|
Total revenues |
|
$ |
5,143 |
|
|
|
$ |
5,685 |
|
|
$ |
10,691 |
|
|
|
$ |
10,966 |
|
|
|
Net income (loss) attributable to Gilead |
|
$ |
(3,339 |
) |
|
|
$ |
1,880 |
|
|
$ |
(1,788 |
) |
|
|
$ |
3,855 |
|
|
|
Non-GAAP net income attributable to Gilead(1) |
|
$ |
1,400 |
|
|
|
$ |
2,196 |
|
|
$ |
3,539 |
|
|
|
$ |
4,337 |
|
|
|
Diluted earnings (loss) per share |
|
$ |
(2.66 |
) |
|
|
$ |
1.47 |
|
|
$ |
(1.42 |
) |
|
|
$ |
3.01 |
|
|
|
Non-GAAP diluted earnings per share(1) |
|
$ |
1.11 |
|
|
|
$ |
1.72 |
|
|
$ |
2.80 |
|
|
|
$ |
3.39 |
|
|
|
________________________________ |
|
(1) Starting in 2020, Gilead no longer regularly excludes share-based compensation expense from its non-GAAP financial information. To conform to this change, the prior period non-GAAP financial information has been recast to include share-based compensation expense. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 12 through 14. |
Total Product Sales
Total product sales reflected a solid financial performance, despite the global impacts of COVID-19. Total product sales decreased 10% to $5.1 billion for the second quarter 2020 and 3% to $10.5 billion for the first half 2020, compared to $5.6 billion and $10.8 billion, respectively, for the same periods in 2019.
-
The decreases were primarily driven by:
- Lower sales volume of chronic hepatitis C virus (“HCV”) products due to COVID-19, which led to fewer healthcare provider (“HCP”) visits and screenings;
- Lower sales of Letairis® (ambrisentan 5 mg and 10 mg) and Ranexa® (ranolazine 500 mg and 1000 mg) after generic entries in the first half 2019; and
- Approximately $160 million of favorable adjustments for statutory rebates primarily related to HCV and HIV sales recorded in Europe in the second quarter 2019, which did not reoccur in 2020.
-
The decreases were partially offset by:
- Underlying demand growth in the core HIV business, with continued patient uptake of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), and Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) for pre-exposure prophylaxis (“PrEP”).
HIV product sales decreased 1% to $4.0 billion for the second quarter 2020 and increased 6% to $8.1 billion for the first half 2020, compared to $4.0 billion and $7.7 billion, respectively, for the same periods in 2019. The increases in the first half 2020, despite the global impacts of COVID-19, were primarily due to the underlying strength of the HIV franchise as demonstrated by increases in Biktarvy share and overall Gilead treatment share in the U.S.
Second Quarter
-
The decreases for the second quarter 2020 were driven by:
- Lower sales volume of Truvada® (emtricitabine (“FTC”) and tenofovir disoproxil fumarate (“TDF”))-based products;
- COVID-19 impact including lower PrEP demand, driven by reduced initiations and therapy discontinuations due to reduced HCP visits and impact on social dynamics;
- Unfavorable payer mix in the U.S.;
- The reversal of the pull forward of revenues into the first quarter due to COVID-19, as outlined in Gilead’s prior quarter earnings release; and
- The favorable adjustments for statutory rebates in Europe recorded in the second quarter 2019.
- The decreases were substantially offset by the continued patient uptake of Biktarvy and Descovy for PrEP®.
First Half
The HIV franchise demonstrated growth of 6% in the first half 2020 compared to prior year, driven by increased demand including for Biktarvy.
-
The increases were partially offset by:
- Lower sales volume of Truvada (FTC/TDF)-based products;
- Lower average net selling price; and
- The favorable adjustments for statutory rebates recorded during the second quarter 2019.
-
COVID-19 primarily impacted PrEP, driven by reduced initiations and therapy discontinuations, and to a lesser degree resulted in reduced HIV treatment switches.
HCV product sales decreased 47% to $448 million for the second quarter 2020 and 28% to $1.2 billion for the first half 2020, compared to $842 million and $1.6 billion, respectively, for the same periods in 2019.
-
The decreases were primarily due to:
- Lower sales volume driven by lower patient starts in the U.S. and Europe attributable to a decrease in HCP visits and screenings due to COVID-19;
- Lower average net selling price; and
- The second quarter 2019 favorable adjustments for statutory rebates recorded in Europe.
Yescarta® (axicabtagene ciloleucel) generated $156 million and $296 million in sales during the second quarter and first half 2020, respectively, compared to $120 million and $216 million, respectively, for the same periods in 2019. The increases were primarily driven by the continued uptake in Europe.
Product Sales by Geography
U.S. product sales decreased 7% to $3.8 billion for the second quarter 2020 and 1% to $7.8 billion for the first half 2020, compared to the same periods in 2019.
-
The decreases were primarily due to:
- Lower sales of Letairis and Ranexa after generic entries in the first half 2019;
- Lower sales volume of HCV products driven by lower patient starts attributable to a decrease in HCP visits and screenings due to COVID-19; and
- The reversal of the pull forward of revenues into the first quarter due to COVID-19, as outlined in Gilead’s prior quarter release.
- The decreases were partially offset by HIV treatment demand growth driven by the continued patient uptake of Biktarvy and the increased usage of Descovy for PrEP.
Europe product sales decreased 30% to $724 million for the second quarter 2020 and 14% to $1.7 billion for the first half 2020, compared to the same periods in 2019.
- The decreases were primarily due to lower sales volume of HCV products driven by lower patient starts due to COVID-19. The decreases were also impacted by the second quarter 2019 favorable adjustments for statutory rebates.
Other international product sales increased 12% to $573 million for the second quarter 2020 and 9% to $1.1 billion, for the first half 2020, compared to the same periods in 2019.
- The increases were primarily due to higher sales volume of Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), Biktarvy and Vemlidy® (tenofovir alafenamide 25 mg), partially offset by lower average net selling price.
|
Operating Expenses |
|||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||
|
(In millions) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||
|
Research and development expenses (“R&D”)(1) |
|
$ |
1,299 |
|
|
$ |
995 |
|
|
$ |
2,303 |
|
|
$ |
1,926 |
|
|
|
Non-GAAP R&D expenses |
|
$ |
1,186 |
|
|
$ |
996 |
|
|
$ |
2,190 |
|
|
$ |
1,928 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Acquired IPR&D expenses(1) |
|
$ |
4,524 |
|
|
$ |
165 |
|
|
$ |
4,621 |
|
|
$ |
291 |
|
|
|
Non-GAAP Acquired IPR&D expenses(1) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Selling, general and administrative expenses (“SG&A”) |
|
$ |
1,239 |
|
|
$ |
1,095 |
|
|
$ |
2,315 |
|
|
$ |
2,125 |
|
|
|
Non-GAAP SG&A expenses |
|
$ |
1,164 |
|
|
$ |
1,096 |
|
|
$ |
2,240 |
|
|
$ |
2,126 |
|
|
|
________________________________ |
|
(1) Beginning in the second quarter 2020, Acquired IPR&D expenses were reported separately from R&D expenses in Gilead’s Condensed Consolidated Statements of Operations to provide additional information. Prior periods have been recast to reflect the change. Acquired IPR&D expenses reflect IPR&D impairments as well as the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects. Acquired IPR&D expenses are excluded from Gilead’s Non-GAAP financial information. |
During the second quarter 2020, compared to the same period in 2019:
- R&D expenses and non-GAAP R&D expenses increased primarily due to higher clinical trial and manufacturing ramp-up expenses related to remdesivir, partially offset by lower clinical trial expenses from other pipeline programs as a result of Gilead’s pause or postponement of other clinical trials during the COVID-19 pandemic.
- Acquired IPR&D expenses increased primarily due to a $4.5 billion charge recorded in connection with Gilead’s acquisition of Forty Seven.
- SG&A expenses and non-GAAP SG&A expenses for the second quarter 2020 increased primarily driven by a $97 million accrual related to a previously disclosed Department of Justice investigation and certain remdesivir donations, partially offset by lower operating expenses due to COVID-19. In addition, the SG&A expenses in the second quarter 2020 reflect increased expenses as a result of the acquisition of Forty Seven.
|
Other Income (Expense), Net |
|||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||
|
(In millions) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||
|
Other income (expense), net |
|
$ |
250 |
|
|
$ |
228 |
|
|
$ |
92 |
|
|
$ |
595 |
|
|
|
Non-GAAP other income (expense), net |
|
$ |
49 |
|
|
$ |
171 |
|
|
$ |
174 |
|
|
$ |
341 |
|
|
During the second quarter 2020, compared to the same period in 2019:
- Other income (expense), net increased by $22 million primarily due to favorable changes in the fair value of investments in equity securities, partially offset by lower interest income.
- Non-GAAP Other income (expense), net decreased by $122 million primarily due to lower interest income.
Effective Tax Rate
The GAAP effective tax rate (“ETR”) and non-GAAP ETR for the second quarter 2020 were (12.5)% and 22.8%, respectively, compared to 22.2% and 21.5% for the same period in 2019, respectively. The negative GAAP ETR for the second quarter 2020 was primarily due to a non-deductible $4.5 billion IPR&D charge related to Gilead’s acquisition of Forty Seven. The year-over-year increase in non-GAAP ETR is primarily due to a shift in jurisdictional mix of earnings.
Cash, Cash Equivalents and Marketable Debt Securities
As of June 30, 2020, Gilead had $21.2 billion of cash, cash equivalents and marketable debt securities, compared to $25.8 billion as of December 31, 2019. During the second quarter 2020, Gilead generated $2.6 billion in operating cash flow, utilized $4.8 billion primarily related to the acquisition of Forty Seven, paid cash dividends of $856 million and utilized $54 million on stock repurchases.
Revised Full Year 2020 Guidance
Gilead revised its full year 2020 guidance, initially provided on February 4, 2020.
|
(In millions, except percentages and per share amounts) |
|
Initially Provided |
|
Updated |
|
|
Product Sales |
|
$21,800 – $22,200 |
|
$23,000 – $25,000 |
|
|
Non-GAAP |
|
|
|
|
|
|
Product Gross Margin |
|
86% – 87% |
|
86% – 87% |
|
|
R&D Expenses |
|
Mid-single digit percentage growth |
|
Mid-teens percentage growth |
|
|
SG&A Expenses |
|
Mid-single digit percentage growth |
|
High-single digit percentage growth |
|
|
Operating Income |
|
$10,100 – $10,800 |
|
$10,700 – $13,000 |
|
|
Effective Tax Rate |
|
~ 21% |
|
~ 21% |
|
|
Diluted EPS |
|
$6.05 – $6.45 |
|
$6.25 – $7.65 |
|
|
GAAP Diluted EPS |
|
$5.15 – $5.55 |
|
$0.83 – $2.23 |
COVID-19 Outlook
The impact of COVID-19 on Gilead’s business continues to be subject to a high degree of uncertainty given unpredictable dynamics related to the incidence, spread and efforts to treat COVID-19 around the world. However, Gilead is in a strong position due to underlying demand drivers, its level of product differentiation and patient benefit in Gilead’s core HIV franchise. Gilead expects a gradual recovery in HIV PrEP. In HCV, Gilead expects patient starts to re-gain momentum in the third quarter 2020 and beyond.
Business Highlights
During the second quarter 2020, Gilead made important strides in advancing work across each of three long-term ambitions laid out in its corporate strategy: (i) to bring 10+ transformative therapies to patients by 2030; (ii) to be the biotech employer and partner of choice; and (iii) to deliver shareholder value in a sustainable and responsible manner. This progress occurred amid challenges posed by the COVID-19 pandemic and an increased focus across the organization on rapidly advancing remdesivir to ensure rapid and broad access for patients, subject to clinical trial outcomes and regulatory approvals.
Corporate Development:
Gilead completed an acquisition and entered into several strategic transactions during the second quarter 2020 to develop a robust immuno-oncology portfolio.
- In April 2020, Gilead completed its acquisition of Forty Seven. Pursuant to the acquisition, Gilead gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers.
- In May 2020, Gilead entered into a transaction to establish a 10-year partnership with Arcus Biosciences, Inc (“Arcus”). Under the terms of the transaction, which closed in July 2020, Gilead made an upfront payment of $175 million and acquired 6 million additional shares of Arcus’ common stock for $200 million. Arcus is building a portfolio of novel investigational products that target important mechanisms involved in tumor evasion of the immune system and developing drug candidates that target cell-intrinsic pathways important for cancer growth and metastasis. Arcus is also advancing antibody products that target immune checkpoint receptors, including PD-(L)1 and TIGIT. Gilead has the right to opt-in to all current and future investigational product candidates that emerge from Arcus’ research portfolio for the ten years following the closing of the transaction. Upon Gilead’s exercise of an option for a program, unless Arcus opts out according to terms of the transaction, the companies will co-develop and share global development costs and will co-commercialize and share profits in the U.S.
- Gilead and Kite Pharma Inc. (“Kite”), a Gilead company, entered into two additional agreements to further advance their immuno-oncology pipeline: a three-year cancer immunotherapy research collaboration with oNKo-innate to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer cells; and a license and collaboration agreement with Teneobio, Inc. (“Teneobio”), to collaborate on next-generation dual-targeting chimeric antigen receptor (“CAR”) T cell therapies in multiple myeloma utilizing Teneobio’s UniAb antibodies.
- In June 2020, Gilead entered into a transaction with Pionyr Immunotherapeutics, Inc. (“Pionyr”), a privately held company pursuing novel biology in the field of immuno-oncology. Subsequently, on July 13, 2020, Gilead closed the transaction and acquired a 49.9% equity interest in Pionyr and an exclusive option to purchase the remainder of Pionyr. Under the terms of the transaction, Gilead will pay $275 million in cash to Pionyr’s shareholders, subject to certain customary adjustments. From the first anniversary of the closing date, Gilead may choose to exercise its option to purchase the remaining equity interest from Pionyr’s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Pionyr’s Myeloid Tuning™ therapies have the potential to treat patients who currently do not benefit from checkpoint inhibitor therapies.
- In an event subsequent to the second quarter 2020, in July 2020, Gilead entered into a transaction with Tizona Therapeutics, Inc. (“Tizona”), a privately held company developing cancer immunotherapies. Under the terms of the transaction, Gilead will pay $300 million in cash to Tizona’s shareholders, subject to certain customary adjustments, and it will obtain a 49.9% equity interest in Tizona and an exclusive option to purchase the remainder of Tizona. From the first anniversary of the closing date, Gilead may choose to exercise its option to purchase the remaining equity interest from Tizona’s current shareholders for up to $1.3 billion, including an option fee and potential future milestone payments, in each case subject to certain negotiated adjustments. The transaction is expected to close in the third quarter 2020, subject to regulatory approvals and other customary closing conditions.
Remdesivir and Gilead’s Ongoing COVID-19 Pandemic Response:
Ensuring Broader Access to Remdesivir.
- Regulatory approvals and authorizations of remdesivir for the treatment of COVID-19 continue to facilitate broader access to remdesivir. In May 2020, the U.S. Food and Drug Administration (“FDA”) issued an Emergency Use Authorization (“EUA”) for Veklury® (remdesivir), an investigational antiviral for the treatment of hospitalized patients with severe COVID-19. The EUA is temporary and does not take the place of the formal new drug application submission, review and approval process. Veklury (remdesivir) has not been approved by FDA for any use. Following FDA’s issuance of the EUA, in May 2020, the Japanese Ministry of Health, Labour and Welfare granted regulatory approval of Veklury (remdesivir) for the treatment of patients with severe COVID-19 under an exceptional approval pathway. In addition, in July 2020, the European Commission granted conditional Marketing Authorization for Veklury (remdesivir) for the treatment of COVID-19, which represents the first approved treatment for COVID-19 in the European Union.
- Gilead completed delivery of its previously announced donation of its initial supply of 1.5 million doses of remdesivir at the end of June 2020. As Gilead transitions beyond this donation, Gilead set the pricing of Veklury (remdesivir) at $390 per vial for governments of developed countries and $520 per vial for U.S. private insurance companies and others. To facilitate broad and equitable access, the pricing was set well below the value that Gilead believes it provides to the healthcare system. In the developing world, Gilead has entered into agreements with generic manufacturers to deliver remdesivir at a substantially lower cost.
- In June 2020, Gilead entered into an agreement with the U.S. Department of Health and Human Services (“HHS”) to make available for purchase more than 500,000 treatment courses through the end of September 2020, allowing American hospitals to purchase Veklury (remdesivir) in amounts allocated by HHS as identified by state health departments. In July 2020, Gilead entered into an agreement with the European Commission to enable the European Commission to centrally purchase Veklury (remdesivir) over the next few months under the Emergency Support Instrument for allocation to European Union member states and the United Kingdom.
- In order to expand manufacturing production and broadly supply remdesivir, Gilead implemented process refinements to substantially shorten the manufacturing lead time from raw materials to finished product. Gilead has also supplemented internal manufacturing with significant additional capacity from multiple partners in North America, Europe and Asia. Gilead currently expects to have manufactured more than two million remdesivir treatment courses by the end of 2020, and several million more treatment courses in 2021.
Advancing Remdesivir Clinical Development:
Gilead made rapid progress in advancing remdesivir as a potential treatment for COVID-19, and during the second quarter 2020, data were released from several key trials that further enhance the understanding of remdesivir and point to its important role in treating patients with COVID-19.
- In June 2020, Gilead announced the results from the Phase 3 SIMPLE trial evaluating five-day and ten-day dosing durations of remdesivir in hospitalized patients with moderate COVID-19 pneumonia. The study demonstrated that the five-day treatment course resulted in significantly greater clinical improvement versus treatment with standard of care alone. These data corroborate the results from the first Gilead Phase 3 SIMPLE study, announced in April 2020, which demonstrated similar clinical improvements in remdesivir-treated patients with severe symptoms of COVID-19, regardless of whether they received a five-day or ten-day treatment course.
- In April 2020, the U.S. National Institute of Allergy and Infectious Diseases announced that preliminary results from their global, placebo-controlled trial of remdesivir met the primary endpoint, and remdesivir was found to shorten the time to recovery for hospitalized patients with COVID-19 when compared to placebo. In addition, the New England Journal of Medicine published data on 53 patients treated with remdesivir through the compassionate use program, which demonstrated clinical improvement and no new safety signals.
- Gilead has a plan for the next wave of remdesivir clinical development, which will study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups. Gilead announced initiation of a Phase 1a clinical study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir in healthy volunteers.
- Gilead also announced the company’s plans for trials using intravenous infusions in outpatient settings such as infusion centers and nursing homes; trials evaluating remdesivir in combination with the JAK inhibitor, baricitinib, and the IL-6 receptor antagonist tocilizumab; and trials including vulnerable patient populations, such as children, pregnant women and patients with end-stage renal disease.
Other Pipeline Updates:
Gilead continued to make progress with its pipeline programs during the second quarter 2020.
- In oncology, new data were presented at the 2020 American Society of Clinical Oncology Annual Meeting highlighting Kite’s leading cell therapy portfolio and magrolimab, the investigational antibody gained through the Forty Seven acquisition.
Contacts
Investors
Adam Levy, MBA, Ph.D.
(650) 574-3000
Douglas Maffei, Ph.D.
(650) 574-3000
Media
Amy Flood
(650) 522-5643
Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results
July 30, 2020Second Quarter and First Half 2020
– Second Quarter Product Sales of $5.1 billion –
– First Half Product Sales of $10.5 billion –
– Second Quarter GAAP Loss of $(2.66) per share –
– Second Quarter Non-GAAP Diluted EPS of $1.11 per share –
Revised Full Year 2020 Guidance
– Product Sales of $23 billion to $25 billion –
– Non-GAAP Diluted EPS of $6.25 to $7.65 per share –
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020.
“Gilead’s first half performance demonstrates the strength and durability of our core HIV business, even as we navigated the expected impact of the COVID-19 pandemic. We are already starting to see early signs of recovery from this impact and we are fully confident in our long-term HIV leadership,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. (Read more…) “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”
Financial Results
- Total revenues for the second quarter and first half 2020 were $5.1 billion and $10.7 billion, respectively, compared to $5.7 billion and $11.0 billion, respectively, for the same periods in 2019.
- GAAP net loss and diluted loss per share for the second quarter 2020 were $(3.3) billion and $(2.66), respectively, compared to net income and diluted EPS of $1.9 billion and $1.47, respectively, for the same period in 2019.
- GAAP net loss for the second quarter 2020 included an acquired in-process research and development (“IPR&D”) charge of $4.5 billion related to Gilead’s acquisition of Forty Seven, Inc (“Forty Seven”).
- Non-GAAP net income and diluted EPS for the second quarter 2020 were $1.4 billion and $1.11, respectively, compared to $2.2 billion and $1.72, respectively, for the same period in 2019.
- Gilead’s core business delivered a solid performance, despite the global impacts of COVID-19.
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||||
|
(In millions, except per share amounts) |
|
2020 |
|
|
2019 |
|
2020 |
|
|
2019 |
|||||||||
|
Product sales |
|
$ |
5,067 |
|
|
|
$ |
5,607 |
|
|
$ |
10,534 |
|
|
|
$ |
10,807 |
|
|
|
Royalty, contract and other revenues |
|
76 |
|
|
|
78 |
|
|
157 |
|
|
|
159 |
|
|||||
|
Total revenues |
|
$ |
5,143 |
|
|
|
$ |
5,685 |
|
|
$ |
10,691 |
|
|
|
$ |
10,966 |
|
|
|
Net income (loss) attributable to Gilead |
|
$ |
(3,339 |
) |
|
|
$ |
1,880 |
|
|
$ |
(1,788 |
) |
|
|
$ |
3,855 |
|
|
|
Non-GAAP net income attributable to Gilead(1) |
|
$ |
1,400 |
|
|
|
$ |
2,196 |
|
|
$ |
3,539 |
|
|
|
$ |
4,337 |
|
|
|
Diluted earnings (loss) per share |
|
$ |
(2.66 |
) |
|
|
$ |
1.47 |
|
|
$ |
(1.42 |
) |
|
|
$ |
3.01 |
|
|
|
Non-GAAP diluted earnings per share(1) |
|
$ |
1.11 |
|
|
|
$ |
1.72 |
|
|
$ |
2.80 |
|
|
|
$ |
3.39 |
|
|
|
________________________________ |
|
(1) Starting in 2020, Gilead no longer regularly excludes share-based compensation expense from its non-GAAP financial information. To conform to this change, the prior period non-GAAP financial information has been recast to include share-based compensation expense. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 12 through 14. |
Total Product Sales
Total product sales reflected a solid financial performance, despite the global impacts of COVID-19. Total product sales decreased 10% to $5.1 billion for the second quarter 2020 and 3% to $10.5 billion for the first half 2020, compared to $5.6 billion and $10.8 billion, respectively, for the same periods in 2019.
-
The decreases were primarily driven by:
- Lower sales volume of chronic hepatitis C virus (“HCV”) products due to COVID-19, which led to fewer healthcare provider (“HCP”) visits and screenings;
- Lower sales of Letairis® (ambrisentan 5 mg and 10 mg) and Ranexa® (ranolazine 500 mg and 1000 mg) after generic entries in the first half 2019; and
- Approximately $160 million of favorable adjustments for statutory rebates primarily related to HCV and HIV sales recorded in Europe in the second quarter 2019, which did not reoccur in 2020.
-
The decreases were partially offset by:
- Underlying demand growth in the core HIV business, with continued patient uptake of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), and Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) for pre-exposure prophylaxis (“PrEP”).
HIV product sales decreased 1% to $4.0 billion for the second quarter 2020 and increased 6% to $8.1 billion for the first half 2020, compared to $4.0 billion and $7.7 billion, respectively, for the same periods in 2019. The increases in the first half 2020, despite the global impacts of COVID-19, were primarily due to the underlying strength of the HIV franchise as demonstrated by increases in Biktarvy share and overall Gilead treatment share in the U.S.
Second Quarter
-
The decreases for the second quarter 2020 were driven by:
- Lower sales volume of Truvada® (emtricitabine (“FTC”) and tenofovir disoproxil fumarate (“TDF”))-based products;
- COVID-19 impact including lower PrEP demand, driven by reduced initiations and therapy discontinuations due to reduced HCP visits and impact on social dynamics;
- Unfavorable payer mix in the U.S.;
- The reversal of the pull forward of revenues into the first quarter due to COVID-19, as outlined in Gilead’s prior quarter earnings release; and
- The favorable adjustments for statutory rebates in Europe recorded in the second quarter 2019.
- The decreases were substantially offset by the continued patient uptake of Biktarvy and Descovy for PrEP®.
First Half
The HIV franchise demonstrated growth of 6% in the first half 2020 compared to prior year, driven by increased demand including for Biktarvy.
-
The increases were partially offset by:
- Lower sales volume of Truvada (FTC/TDF)-based products;
- Lower average net selling price; and
- The favorable adjustments for statutory rebates recorded during the second quarter 2019.
-
COVID-19 primarily impacted PrEP, driven by reduced initiations and therapy discontinuations, and to a lesser degree resulted in reduced HIV treatment switches.
HCV product sales decreased 47% to $448 million for the second quarter 2020 and 28% to $1.2 billion for the first half 2020, compared to $842 million and $1.6 billion, respectively, for the same periods in 2019.
-
The decreases were primarily due to:
- Lower sales volume driven by lower patient starts in the U.S. and Europe attributable to a decrease in HCP visits and screenings due to COVID-19;
- Lower average net selling price; and
- The second quarter 2019 favorable adjustments for statutory rebates recorded in Europe.
Yescarta® (axicabtagene ciloleucel) generated $156 million and $296 million in sales during the second quarter and first half 2020, respectively, compared to $120 million and $216 million, respectively, for the same periods in 2019. The increases were primarily driven by the continued uptake in Europe.
Product Sales by Geography
U.S. product sales decreased 7% to $3.8 billion for the second quarter 2020 and 1% to $7.8 billion for the first half 2020, compared to the same periods in 2019.
-
The decreases were primarily due to:
- Lower sales of Letairis and Ranexa after generic entries in the first half 2019;
- Lower sales volume of HCV products driven by lower patient starts attributable to a decrease in HCP visits and screenings due to COVID-19; and
- The reversal of the pull forward of revenues into the first quarter due to COVID-19, as outlined in Gilead’s prior quarter release.
- The decreases were partially offset by HIV treatment demand growth driven by the continued patient uptake of Biktarvy and the increased usage of Descovy for PrEP.
Europe product sales decreased 30% to $724 million for the second quarter 2020 and 14% to $1.7 billion for the first half 2020, compared to the same periods in 2019.
- The decreases were primarily due to lower sales volume of HCV products driven by lower patient starts due to COVID-19. The decreases were also impacted by the second quarter 2019 favorable adjustments for statutory rebates.
Other international product sales increased 12% to $573 million for the second quarter 2020 and 9% to $1.1 billion, for the first half 2020, compared to the same periods in 2019.
- The increases were primarily due to higher sales volume of Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), Biktarvy and Vemlidy® (tenofovir alafenamide 25 mg), partially offset by lower average net selling price.
|
Operating Expenses |
|||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||
|
(In millions) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||
|
Research and development expenses (“R&D”)(1) |
|
$ |
1,299 |
|
|
$ |
995 |
|
|
$ |
2,303 |
|
|
$ |
1,926 |
|
|
|
Non-GAAP R&D expenses |
|
$ |
1,186 |
|
|
$ |
996 |
|
|
$ |
2,190 |
|
|
$ |
1,928 |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Acquired IPR&D expenses(1) |
|
$ |
4,524 |
|
|
$ |
165 |
|
|
$ |
4,621 |
|
|
$ |
291 |
|
|
|
Non-GAAP Acquired IPR&D expenses(1) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Selling, general and administrative expenses (“SG&A”) |
|
$ |
1,239 |
|
|
$ |
1,095 |
|
|
$ |
2,315 |
|
|
$ |
2,125 |
|
|
|
Non-GAAP SG&A expenses |
|
$ |
1,164 |
|
|
$ |
1,096 |
|
|
$ |
2,240 |
|
|
$ |
2,126 |
|
|
|
________________________________ |
|
(1) Beginning in the second quarter 2020, Acquired IPR&D expenses were reported separately from R&D expenses in Gilead’s Condensed Consolidated Statements of Operations to provide additional information. Prior periods have been recast to reflect the change. Acquired IPR&D expenses reflect IPR&D impairments as well as the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects. Acquired IPR&D expenses are excluded from Gilead’s Non-GAAP financial information. |
During the second quarter 2020, compared to the same period in 2019:
- R&D expenses and non-GAAP R&D expenses increased primarily due to higher clinical trial and manufacturing ramp-up expenses related to remdesivir, partially offset by lower clinical trial expenses from other pipeline programs as a result of Gilead’s pause or postponement of other clinical trials during the COVID-19 pandemic.
- Acquired IPR&D expenses increased primarily due to a $4.5 billion charge recorded in connection with Gilead’s acquisition of Forty Seven.
- SG&A expenses and non-GAAP SG&A expenses for the second quarter 2020 increased primarily driven by a $97 million accrual related to a previously disclosed Department of Justice investigation and certain remdesivir donations, partially offset by lower operating expenses due to COVID-19. In addition, the SG&A expenses in the second quarter 2020 reflect increased expenses as a result of the acquisition of Forty Seven.
|
Other Income (Expense), Net |
|||||||||||||||||
|
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||||||
|
|
|
June 30, |
|
June 30, |
|||||||||||||
|
(In millions) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
|||||||||
|
Other income (expense), net |
|
$ |
250 |
|
|
$ |
228 |
|
|
$ |
92 |
|
|
$ |
595 |
|
|
|
Non-GAAP other income (expense), net |
|
$ |
49 |
|
|
$ |
171 |
|
|
$ |
174 |
|
|
$ |
341 |
|
|
During the second quarter 2020, compared to the same period in 2019:
- Other income (expense), net increased by $22 million primarily due to favorable changes in the fair value of investments in equity securities, partially offset by lower interest income.
- Non-GAAP Other income (expense), net decreased by $122 million primarily due to lower interest income.
Effective Tax Rate
The GAAP effective tax rate (“ETR”) and non-GAAP ETR for the second quarter 2020 were (12.5)% and 22.8%, respectively, compared to 22.2% and 21.5% for the same period in 2019, respectively. The negative GAAP ETR for the second quarter 2020 was primarily due to a non-deductible $4.5 billion IPR&D charge related to Gilead’s acquisition of Forty Seven. The year-over-year increase in non-GAAP ETR is primarily due to a shift in jurisdictional mix of earnings.
Cash, Cash Equivalents and Marketable Debt Securities
As of June 30, 2020, Gilead had $21.2 billion of cash, cash equivalents and marketable debt securities, compared to $25.8 billion as of December 31, 2019. During the second quarter 2020, Gilead generated $2.6 billion in operating cash flow, utilized $4.8 billion primarily related to the acquisition of Forty Seven, paid cash dividends of $856 million and utilized $54 million on stock repurchases.
Revised Full Year 2020 Guidance
Gilead revised its full year 2020 guidance, initially provided on February 4, 2020.
|
(In millions, except percentages and per share amounts) |
|
Initially Provided |
|
Updated |
|
|
Product Sales |
|
$21,800 – $22,200 |
|
$23,000 – $25,000 |
|
|
Non-GAAP |
|
|
|
|
|
|
Product Gross Margin |
|
86% – 87% |
|
86% – 87% |
|
|
R&D Expenses |
|
Mid-single digit percentage growth |
|
Mid-teens percentage growth |
|
|
SG&A Expenses |
|
Mid-single digit percentage growth |
|
High-single digit percentage growth |
|
|
Operating Income |
|
$10,100 – $10,800 |
|
$10,700 – $13,000 |
|
|
Effective Tax Rate |
|
~ 21% |
|
~ 21% |
|
|
Diluted EPS |
|
$6.05 – $6.45 |
|
$6.25 – $7.65 |
|
|
GAAP Diluted EPS |
|
$5.15 – $5.55 |
|
$0.83 – $2.23 |
COVID-19 Outlook
The impact of COVID-19 on Gilead’s business continues to be subject to a high degree of uncertainty given unpredictable dynamics related to the incidence, spread and efforts to treat COVID-19 around the world. However, Gilead is in a strong position due to underlying demand drivers, its level of product differentiation and patient benefit in Gilead’s core HIV franchise. Gilead expects a gradual recovery in HIV PrEP. In HCV, Gilead expects patient starts to re-gain momentum in the third quarter 2020 and beyond.
Business Highlights
During the second quarter 2020, Gilead made important strides in advancing work across each of three long-term ambitions laid out in its corporate strategy: (i) to bring 10+ transformative therapies to patients by 2030; (ii) to be the biotech employer and partner of choice; and (iii) to deliver shareholder value in a sustainable and responsible manner. This progress occurred amid challenges posed by the COVID-19 pandemic and an increased focus across the organization on rapidly advancing remdesivir to ensure rapid and broad access for patients, subject to clinical trial outcomes and regulatory approvals.
Corporate Development:
Gilead completed an acquisition and entered into several strategic transactions during the second quarter 2020 to develop a robust immuno-oncology portfolio.
- In April 2020, Gilead completed its acquisition of Forty Seven. Pursuant to the acquisition, Gilead gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers.
- In May 2020, Gilead entered into a transaction to establish a 10-year partnership with Arcus Biosciences, Inc (“Arcus”). Under the terms of the transaction, which closed in July 2020, Gilead made an upfront payment of $175 million and acquired 6 million additional shares of Arcus’ common stock for $200 million. Arcus is building a portfolio of novel investigational products that target important mechanisms involved in tumor evasion of the immune system and developing drug candidates that target cell-intrinsic pathways important for cancer growth and metastasis. Arcus is also advancing antibody products that target immune checkpoint receptors, including PD-(L)1 and TIGIT. Gilead has the right to opt-in to all current and future investigational product candidates that emerge from Arcus’ research portfolio for the ten years following the closing of the transaction. Upon Gilead’s exercise of an option for a program, unless Arcus opts out according to terms of the transaction, the companies will co-develop and share global development costs and will co-commercialize and share profits in the U.S.
- Gilead and Kite Pharma Inc. (“Kite”), a Gilead company, entered into two additional agreements to further advance their immuno-oncology pipeline: a three-year cancer immunotherapy research collaboration with oNKo-innate to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer cells; and a license and collaboration agreement with Teneobio, Inc. (“Teneobio”), to collaborate on next-generation dual-targeting chimeric antigen receptor (“CAR”) T cell therapies in multiple myeloma utilizing Teneobio’s UniAb antibodies.
- In June 2020, Gilead entered into a transaction with Pionyr Immunotherapeutics, Inc. (“Pionyr”), a privately held company pursuing novel biology in the field of immuno-oncology. Subsequently, on July 13, 2020, Gilead closed the transaction and acquired a 49.9% equity interest in Pionyr and an exclusive option to purchase the remainder of Pionyr. Under the terms of the transaction, Gilead will pay $275 million in cash to Pionyr’s shareholders, subject to certain customary adjustments. From the first anniversary of the closing date, Gilead may choose to exercise its option to purchase the remaining equity interest from Pionyr’s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Pionyr’s Myeloid Tuning™ therapies have the potential to treat patients who currently do not benefit from checkpoint inhibitor therapies.
- In an event subsequent to the second quarter 2020, in July 2020, Gilead entered into a transaction with Tizona Therapeutics, Inc. (“Tizona”), a privately held company developing cancer immunotherapies. Under the terms of the transaction, Gilead will pay $300 million in cash to Tizona’s shareholders, subject to certain customary adjustments, and it will obtain a 49.9% equity interest in Tizona and an exclusive option to purchase the remainder of Tizona. From the first anniversary of the closing date, Gilead may choose to exercise its option to purchase the remaining equity interest from Tizona’s current shareholders for up to $1.3 billion, including an option fee and potential future milestone payments, in each case subject to certain negotiated adjustments. The transaction is expected to close in the third quarter 2020, subject to regulatory approvals and other customary closing conditions.
Remdesivir and Gilead’s Ongoing COVID-19 Pandemic Response:
Ensuring Broader Access to Remdesivir.
- Regulatory approvals and authorizations of remdesivir for the treatment of COVID-19 continue to facilitate broader access to remdesivir. In May 2020, the U.S. Food and Drug Administration (“FDA”) issued an Emergency Use Authorization (“EUA”) for Veklury® (remdesivir), an investigational antiviral for the treatment of hospitalized patients with severe COVID-19. The EUA is temporary and does not take the place of the formal new drug application submission, review and approval process. Veklury (remdesivir) has not been approved by FDA for any use. Following FDA’s issuance of the EUA, in May 2020, the Japanese Ministry of Health, Labour and Welfare granted regulatory approval of Veklury (remdesivir) for the treatment of patients with severe COVID-19 under an exceptional approval pathway. In addition, in July 2020, the European Commission granted conditional Marketing Authorization for Veklury (remdesivir) for the treatment of COVID-19, which represents the first approved treatment for COVID-19 in the European Union.
- Gilead completed delivery of its previously announced donation of its initial supply of 1.5 million doses of remdesivir at the end of June 2020. As Gilead transitions beyond this donation, Gilead set the pricing of Veklury (remdesivir) at $390 per vial for governments of developed countries and $520 per vial for U.S. private insurance companies and others. To facilitate broad and equitable access, the pricing was set well below the value that Gilead believes it provides to the healthcare system. In the developing world, Gilead has entered into agreements with generic manufacturers to deliver remdesivir at a substantially lower cost.
- In June 2020, Gilead entered into an agreement with the U.S. Department of Health and Human Services (“HHS”) to make available for purchase more than 500,000 treatment courses through the end of September 2020, allowing American hospitals to purchase Veklury (remdesivir) in amounts allocated by HHS as identified by state health departments. In July 2020, Gilead entered into an agreement with the European Commission to enable the European Commission to centrally purchase Veklury (remdesivir) over the next few months under the Emergency Support Instrument for allocation to European Union member states and the United Kingdom.
- In order to expand manufacturing production and broadly supply remdesivir, Gilead implemented process refinements to substantially shorten the manufacturing lead time from raw materials to finished product. Gilead has also supplemented internal manufacturing with significant additional capacity from multiple partners in North America, Europe and Asia. Gilead currently expects to have manufactured more than two million remdesivir treatment courses by the end of 2020, and several million more treatment courses in 2021.
Advancing Remdesivir Clinical Development:
Gilead made rapid progress in advancing remdesivir as a potential treatment for COVID-19, and during the second quarter 2020, data were released from several key trials that further enhance the understanding of remdesivir and point to its important role in treating patients with COVID-19.
- In June 2020, Gilead announced the results from the Phase 3 SIMPLE trial evaluating five-day and ten-day dosing durations of remdesivir in hospitalized patients with moderate COVID-19 pneumonia. The study demonstrated that the five-day treatment course resulted in significantly greater clinical improvement versus treatment with standard of care alone. These data corroborate the results from the first Gilead Phase 3 SIMPLE study, announced in April 2020, which demonstrated similar clinical improvements in remdesivir-treated patients with severe symptoms of COVID-19, regardless of whether they received a five-day or ten-day treatment course.
- In April 2020, the U.S. National Institute of Allergy and Infectious Diseases announced that preliminary results from their global, placebo-controlled trial of remdesivir met the primary endpoint, and remdesivir was found to shorten the time to recovery for hospitalized patients with COVID-19 when compared to placebo. In addition, the New England Journal of Medicine published data on 53 patients treated with remdesivir through the compassionate use program, which demonstrated clinical improvement and no new safety signals.
- Gilead has a plan for the next wave of remdesivir clinical development, which will study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups. Gilead announced initiation of a Phase 1a clinical study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir in healthy volunteers.
- Gilead also announced the company’s plans for trials using intravenous infusions in outpatient settings such as infusion centers and nursing homes; trials evaluating remdesivir in combination with the JAK inhibitor, baricitinib, and the IL-6 receptor antagonist tocilizumab; and trials including vulnerable patient populations, such as children, pregnant women and patients with end-stage renal disease.
Other Pipeline Updates:
Gilead continued to make progress with its pipeline programs during the second quarter 2020.
- In oncology, new data were presented at the 2020 American Society of Clinical Oncology Annual Meeting highlighting Kite’s leading cell therapy portfolio and magrolimab, the investigational antibody gained through the Forty Seven acquisition.
Contacts
Investors
Adam Levy, MBA, Ph.D.
(650) 574-3000
Douglas Maffei, Ph.D.
(650) 574-3000
Media
Amy Flood
(650) 522-5643